BRPI0612897A2 - método para produzir um antígeno covalentemente estabilizado - Google Patents

método para produzir um antígeno covalentemente estabilizado

Info

Publication number
BRPI0612897A2
BRPI0612897A2 BRPI0612897A BRPI0612897A BRPI0612897A2 BR PI0612897 A2 BRPI0612897 A2 BR PI0612897A2 BR PI0612897 A BRPI0612897 A BR PI0612897A BR PI0612897 A BRPI0612897 A BR PI0612897A BR PI0612897 A2 BRPI0612897 A2 BR PI0612897A2
Authority
BR
Brazil
Prior art keywords
produce
covalently stabilized
stabilized antigen
antigen
covalently
Prior art date
Application number
BRPI0612897A
Other languages
English (en)
Inventor
Denise Nawrocki
Joseph G Joyce
Karen M Grimm
Xiaoping Liang
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BRPI0612897A2 publication Critical patent/BRPI0612897A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0007Nervous system antigens; Prions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0612897A 2005-06-30 2006-06-26 método para produzir um antígeno covalentemente estabilizado BRPI0612897A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69552805P 2005-06-30 2005-06-30
PCT/US2006/024742 WO2007005358A2 (en) 2005-06-30 2006-06-26 Method for preparing a covalently cross linked oligomer of amyloid beta peptides

Publications (1)

Publication Number Publication Date
BRPI0612897A2 true BRPI0612897A2 (pt) 2016-11-29

Family

ID=37478826

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0612897A BRPI0612897A2 (pt) 2005-06-30 2006-06-26 método para produzir um antígeno covalentemente estabilizado

Country Status (10)

Country Link
US (1) US20100143396A1 (pt)
EP (1) EP1899371A2 (pt)
JP (1) JP2009500325A (pt)
CN (1) CN101213207A (pt)
AR (1) AR055584A1 (pt)
AU (1) AU2006266212A1 (pt)
BR (1) BRPI0612897A2 (pt)
CA (1) CA2613040A1 (pt)
TW (1) TW200726482A (pt)
WO (1) WO2007005358A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002003911A2 (en) 2000-07-07 2002-01-17 Lars Lannfelt Prevention and treatment of alzheimer's disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
EP2289909B1 (en) 2005-11-30 2014-10-29 AbbVie Inc. Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
KR101667623B1 (ko) 2005-11-30 2016-10-19 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
SI2004688T2 (sl) 2006-03-23 2014-05-30 Bioarctic Neuroscience Ab Izboljšana protofibrilno selektivna protitelesa in njihova uporaba
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
FR2922769A1 (fr) * 2007-10-31 2009-05-01 Halina Malina Modification des sequences intrinsequement desordonnees pour la preparation de vaccins
JP5817060B2 (ja) 2008-04-14 2015-11-18 アルツィノヴァ エービー 精製されたペプチド、精製されたペプチドを含む可溶性オリゴマー、精製されたペプチドあるいは可溶性オリゴマーを利用した、疾患の治療に適した化合物の同定方法、精製されたペプチドあるいは可溶性オリゴマーを利用した、精製されたペプチドあるいは可溶性オリゴマーと反応する結合タンパク質の選択方法、医薬組成物の製造における、精製されたペプチドあるいは可溶性オリゴマーの使用、精製されたペプチドあるいは可溶性オリゴマーを含む医薬製剤、精製されたペプチドあるいは可溶性オリゴマーを含むワクチン、精製されたペプチドあるいは可溶性オリゴマーを利用した、ヒトを除く哺乳動物を予防または治療する方法、appが二つのシステインを含むappをコードするヌクレオチドを発現する、非ヒトトランスジェニック動物、精製されたペプチドをコードするヌクレオチドを発現する、非ヒトトランスジェニック動物、appが二つのシステインを含むappであるポリペプチド、精製されたペプチドまたはポリペプチドをコードするヌクレオチド、精製されたペプチドまたはポリペプチドをコードするヌクレオチドを含む発現系
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
JP5934203B2 (ja) 2010-07-14 2016-06-15 メルク・シャープ・エンド・ドーム・コーポレイション 抗addlモノクローナル抗体およびこの使用
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
US9573994B2 (en) 2014-07-10 2017-02-21 Bioarctic Neuroscience Ab Aβ protofibril binding antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074004A2 (en) * 2002-03-01 2003-09-12 Szu-Yi Chou Method of producing antigens

Also Published As

Publication number Publication date
JP2009500325A (ja) 2009-01-08
WO2007005358A3 (en) 2007-04-05
CA2613040A1 (en) 2007-01-11
AR055584A1 (es) 2007-08-29
EP1899371A2 (en) 2008-03-19
CN101213207A (zh) 2008-07-02
AU2006266212A1 (en) 2007-01-11
TW200726482A (en) 2007-07-16
WO2007005358A2 (en) 2007-01-11
US20100143396A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
CY2019041I2 (el) Τροποποιημενα αντισωματα εναντι il-23
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
CR10705A (es) Anticuerpos para linfotoxina-alfa
BRPI0715917A2 (pt) Anticorpos para il-17a
PL2351578T3 (pl) Sposób wytwarzania szczepionek
NO20076607L (no) TWEAK - bindende antistoff
CY2016030I1 (el) Αντισωματα εναντι της il-17
DK1964852T3 (da) Anti-ilt7-antistof
HRP20150176T1 (xx) Protutijela protiv miostatina
BRPI0719843A2 (pt) Método para a produção de bisbenzoxazóis
LU92389I2 (fr) Cystéamine
BRPI0817427A2 (pt) Anticorpo anti-bst2
BRPI0813858A2 (pt) Método para produzir peptídeo
FI20055616A0 (fi) Menetelmä valmisteen rakenteen muokkaamiseen
BRPI0818674A2 (pt) Método para produção de anticorpos
BRPI0612897A2 (pt) método para produzir um antígeno covalentemente estabilizado
BRPI0610669A2 (pt) método para produzir um produto bruto
DE602006016683D1 (de) Tonerherstellungsverfahren
EP2015785A4 (en) AGRM2 ANTIGEN
FI20065363A0 (fi) Erotusmenetelmä
FI20055650L (fi) Paikannustekniikka
DK2062053T3 (da) Forbedret immunoanalysefremgangsmåde
PL1871804T3 (pl) Przeciwciała wiążące CCX-CKR2
DK1955066T3 (da) Membran-assay-fremgangsmåde
BRPI0614894A2 (pt) método para produzir um composto, e, composto

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B11Z Dismissal: petition dismissal - article 216, par 2 of industrial property law

Free format text: REFERENTE A PETICAO NO 20070185025/RJ DE 28/12/2007.

B11M Decision cancelled [chapter 11.13 patent gazette]

Free format text: O DESPACHO 11.6.1 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.

B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: O DESPACHO 6.7 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 39/00 (2006.01), A61K 47/64 (2017.01)

B350 Update of information on the portal [chapter 15.35 patent gazette]